178P PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent disease
Federica Miglietta(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), M. Fassan(University of Padua), Daniela Iannaccone(University of Padua), Grazia Maria Vernaci(University of Padua), G. Griguolo(University of Padua), Filippo Zanghi(Istituto Oncologico Veneto), Francesca Porra(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), V. Guarneri(University of Padua), A. Righetto(University of Padua), Lorenzo Nicolè(University of Padua), Carlo Alberto Giorgi(Istituto Oncologico Veneto), F. Girardi(Istituto Oncologico Veneto), D. Massa(Istituto Oncologico Veneto), C. Zurlo(University of Padua)
Cited by 0
Related Papers
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
|JNCI Journal of the National Cancer Institute|2019|168
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
|Cancer Treatment Reviews|2016|128